<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331669</url>
  </required_header>
  <id_info>
    <org_study_id>DBS and tardive dystonia</org_study_id>
    <nct_id>NCT00331669</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia</brief_title>
  <official_title>Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Humboldt-Universität zu Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Hannover</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, double blind, multi-center study is to assess the efficacy
      and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deep brain stimulation (DBS) has been established as a new reversible, neurosurgical
      therapeutic option for patients suffering from disabling neurological movement disorders such
      as essential tremor and Parkinson´s disease. Recently, deep brain stimulation has been
      successfully applied in patients with primary generalized and segmental dystonia.
      Additionally, a number of case reports suggest that pallidal deep brain stimulation may also
      improve tardive dystonia, which may for instance result from the intake of neuroleptics and
      which is notoriously difficult to treat medically. The present study will investigate the
      effects of pallidal DBS using a double blind, randomized design (sham- versus
      verum-stimulation within a 3-months interval post implantation of the electrodes).

      Initially 60 patients had been calculated in a power analysis to assess significant results
      based on an average improvement of dystonic symptoms of 30%. However, in a recent study
      (Damier et al., Archives of General Psychiatry, 2007), 10 out of 10 showed a successful
      outcome of approximately 50% decrease on the extrapyramidal symptoms rating scale score. The
      exact one- sided lower 95% confidence limit would be 0.794 for this result. If such an
      approach is chosen for sample size estimation with 18 verum and 18 placebo patients one would
      obtain a power of 82% against a placebo effect of 30% success rate. For a placebo effect of
      25% one needs 16+16 patients and for the placebo effect of 20% one needs 12+12 patients. We
      thus decided to reduce the sample size to 36- 32- 24 patients. It is expected that the
      continuous primary outcome measure will preserve even higher power than the binary one used
      in the study mentioned above. The local ethical committee has approved this.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the motor scale of Burke-Fahn-Marsden-Dystonia Rating Scale via blinded video assessment 3 months after starting DBS in comparison to sham-stimulated patients</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AIMS</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-motor subscores of BMFDRS</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for both patients and treating physicians</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment (HADS-D and PANSS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Dystonia</condition>
  <condition>Movement Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>device</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>deep brain stimulation</intervention_name>
    <description>high frequency stimulation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operational criteria for tardive dystonia for &gt; 18 months after cessation of
             neuroleptic exposure

          -  18-75 years

          -  Relevant functional impairment in daily living activities

          -  BFMDRS &gt; 8 or AIMS &gt; 16

          -  Informed written consent

        Exclusion Criteria:

          -  PANNS &gt;60 (Schizophrenia)

          -  Hamilton-Score &gt; 18 (Depression)

          -  MATTIS-Score &lt;120 (Dementia)

          -  Preceding stereotactic neurosurgery

          -  Pronounced brain atrophy

          -  Increased bleeding risk

          -  Decreased immune status

          -  Botulinum Toxin treatment within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas R Kupsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. of Neurology, Augustenburger Platz 1, 13353 Berlin, Charite, Campus Virchow, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas R Kupsch, MD, PhD</last_name>
    <phone>xx49-30-450-50</phone>
    <phone_ext>660103</phone_ext>
    <email>andreas.kupsch@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Kuehn, MD</last_name>
    <phone>xx49-30-450-50</phone>
    <phone_ext>660203</phone_ext>
    <email>andrea.kuehn@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Andreas Kupsch</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas R Kupsch, MD, PhD</last_name>
      <phone>xx49-30-450-50</phone>
      <phone_ext>660103</phone_ext>
      <email>andreas.kupsch@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Kuehn, MD</last_name>
      <phone>xx49-30-450-50</phone>
      <phone_ext>660203</phone_ext>
      <email>andrea.kuehn@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas R Kupsch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Trottenberg T, Volkmann J, Deuschl G, Kühn AA, Schneider GH, Müller J, Alesch F, Kupsch A. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology. 2005 Jan 25;64(2):344-6.</citation>
    <PMID>15668437</PMID>
  </reference>
  <reference>
    <citation>Franzini A, Marras C, Ferroli P, Zorzi G, Bugiani O, Romito L, Broggi G. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases. J Neurosurg. 2005 Apr;102(4):721-5.</citation>
    <PMID>15871516</PMID>
  </reference>
  <reference>
    <citation>Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, Mertens P, Peragut JC, Lemaire JJ, Burbaud P, Nguyen JM, Llorca PM, Rascol O; French Stimulation for Tardive Dyskinesia (STARDYS) Study Group. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007 Feb;64(2):170-6.</citation>
    <PMID>17283284</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>March 3, 2009</last_update_submitted>
  <last_update_submitted_qc>March 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2009</last_update_posted>
  <keyword>deep brain stimulation</keyword>
  <keyword>pallidum</keyword>
  <keyword>tardive dystonia</keyword>
  <keyword>randomized</keyword>
  <keyword>double blind</keyword>
  <keyword>multicenter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Tardive Dyskinesia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

